Friday, 18 Oct 2019

You are here

Good News from ACR17 - Gout

The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content - http://acr17.rheumnow.com/category/gout-crystal/

Specific items:

  • Treatment of hyperuricemia to prevent incident dementia? Some data suggests this. Abstract #2076
  • PossibleGout and OA connection? Human cartilage increases amount and size of MSU crystals. Abstract #2896 http://ow.ly/ABLg30fM2gw
  • Low Uric acid may raise the risk of dementia. Abstract #2080
  • Lower coffee consumption is associated with gout!  Abstract #2066
  • Allopurinol and Febuxostat in lowes the risk of Dementia. Yes you read that right! Jas Singh et al. Abstract #2076
  • Both generic and environmental factors influence the fractional excretion of uric acid Abstract #2061
  • Hyperuricemia is associated with more rapid knee osteoarthritis progression. A&R 2017
  • Tollerizing pegloticase regimen decreases infusion reactions in the TRIPLE study Abstract #1141
  • Gout is under treated people… need to get better  Abstract #1121
  • If you have gout and type II diabetes you have worse gout. More tophi and erosions. Abstract #1118
  • Uncontrolled gout is associated with more heart failure so treat gout effectively. Abstract #1119
  • Risk for CV events lower with the new start probenecid (rather than allopurinol) for older >65 yo patients Abstract #159
  • Dr. Daniel Solomon YR in Review – the DASH diet decrease gout risk https://doi.org/10.1136/bmj.j1794 
  • Diuretics don’t seem to impact hugely on gout treatment objectives in this study Abstract #1129
  • Patients aren’t getting to urate target in gout when treated with allopurinol. Are we using enough? Abstract #166
  • Do we need to change the label ‘gout’ ?!?!? Has negative stereotypes  Abstract #1107
  • Patients with gout have their XOI stopped when they present with AKI. Evidence free zone and makes gout Rx harder. Abstract #1116
  • Gout patients more likely to achieve sUA goal< 6 mg/dL if managed by a rheumatologist. Go team Rheum! Abstract #166
  • Pre-Rx with methylprednisolone superior to HC as prophylaxis for pegloticase w/ greater drug survival  Abstract #213 https://buff.ly/2hKNl3y
  • Double contour sign - earliest sign of uric acid deposition obs in asymptomatic gout pts. Abstract #250 http://ow.ly/YZtb30fDVzZ
  • US of MTP1, distal patellar/triceps tendons, talar + femoral cartilage for MSU in possible gout Abstract #249
  • FORTUNE1: stepwise  Uloric dose comparable to colchicine+Uloric in flare prevention during introductory Rx 
  • Cankinumab reduces CV events, decreases risk of gout & malignancy. Higher infection risk  #YearInReview
  • “Gout patients can have septic arthritis and sickle cell pts can also have gout. Keep this in mind during your nex sickle cell crisis differential diagnoses.”  – J Cush, MD (Rheumatology Roundup). 

Gout Videos

Dr. Jack Cush: When Asymptomatic Hyperuricemia Should Be Treated 

 

Dr. Arthur Kavanaugh: Gout, OA Posters

 

Dr. Ken Saag: Update on Gout Therapy

 

Dr. Janet Pope: Gout Gamechangers 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.